Nitric oxide has been implicated in numerous biological processes, particularly those involved with the cardiovascular system. Nitric oxide production is closely regulated and influenced by a number of factors in both health and disease. Nitric oxide is involved in maintaining the vascular system in its healthy, nondiseased state by producing vasorelaxation which enhances blood flow and prevents both leukocyte and platelet adhesion to the vascular wall. Dysfunctional endothelial cell nitric oxide production has been implicated in a number of disease states, including hypertension and atherosclerosis, and has been associated with adverse cardiac events. Various recent therapies may exert their beneficial effects in part by enhancing endothelial nitric oxide bloavallability. Nitric oxide has been used therapeutically in a number of cardiorespiratory disease states. An improved understanding of the pathologic processes underlying these diseases has resulted in several alternative agents being investigated and used clinically.
Get full access to this article
View all access options for this article.
References
1.
1. Andrews K, Triggle C, Ellis A: NO and the vasculature: Where does it come from and what does it do?Heart Failure Rev7:423-445, 2002.
2.
2. Moncada S, Palmer RM, Higgs EA: Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol38:1709-1715, 1989.
4. Mitaka C, Yokoyama K, Morimoto T, et al: An increase in urinary nitrite/nitrate excretion is associated with the hyperdynamic state after cardiovascular surgery. Intens Care Med28:1103-1109, 2002.
5.
5. Gow A, Stamler J: Reactions between nitric oxide and hemoglobin under physiological conditions. Nature391:169-173, 1998.
6.
6. Stamler JS, Jia L, Eu JP, et al: Blood flow regulation by Snitrosohemoglobin in the physiological oxygen gradient. Science276:2034-2037, 1997.
7.
7. Behrendt D, Ganz P: Endothelial function: From vascular biology to clinical applications. Am J Cardiol90:L40-L48, 2002.
8.
8. Ricciardolo F: Multiple roles of nitric oxide in the airways. Thorax58:175-182, 2003.
9.
9. Guo FH, De Raeve HR, Rice TW, et al: Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci USA92:7809-7813, 1995.
10.
10. Le Cras TD, Xue C, Rengasamy A, et al: Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol270:L164-L170, 1996.
11.
11. Uematsu M, Ohara Y, Navas J, et al: Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. Am J Physiol269:C1371-C1378, 1995.
12.
12. Ziegler T, Silacci P, Harrison V, et al: Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension32:351-355, 1998.
13.
13. Ruehlmann D, Mann G: Rapid non-genomic vasodilator actions of estrogens and sex steroids. Curr Med Chem7:533-541, 2000.
14.
14. Ramasamy S, Parthasarathy S, Harrison D: Regulation of endothelial nitric oxide synthase gene expression by oxidized linoleic acid. J Lipid Res39:268-276, 1998.
15.
15. Papapetropoulos A, Garcia-Cardena G, Madri J, et al: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest100:3131-3139, 1997.
16.
16. Rogers N, Ignarro L: Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine. Biochem Biophys Res Commun189:242-249, 1992.
17.
17. Bredt D: Nitric oxide signaling specificity-the heart of the problem. J Cell Science116:9-15, 2003.
18.
18. Gewaltig M, Kojda G: Vasoprotection by nitric oxide: Mechanisms and therapeutic potential. Cardiovasc Res55:250-260, 2002.
19.
19. Palmer R, Ferrige A, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature327:524-526, 1987.
20.
20. Kubes P, Suzuki M, Granger D: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA88:4651-4655, 1991.
21.
21. Garg U, Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured vascular smooth muscle cells. J Clin Invest83:1774-1777, 1989.
22.
22. Radomski M, Palmer R, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA87(13):5193-5197, 1990.
23.
23. Ziche M, Morbidelli L: Nitric oxide and angiogenesis. J Neurooncol50:139-148, 2000.
24.
24. Gabbai F: Effect of nitric oxide synthase blockers on renal function. Nephrol Dial Transplant16(Suppl 1):10-13, 2001.
25.
25. Laycock S, Vogel T, Forfia P, et al: Role of nitric oxide in the control of renal oxygen consumption and the regulation of the chemical work in the kidney. Circ Res82:1263-1271, 1998.
27. Adnot S, Raffestin B, Eddamibi S, et al: Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest87:155-162, 1991.
28.
28. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med333:214-221, 1995.
29.
29. Dinh-Xuan A, Higgenbottam T, Clell-and C, et al: Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease. N Engl J Med324:1539-1547, 1991.
30.
30. Kuhlencordt P, Gyurko R, Han F, et al: Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double knockout mice. Circulation104:448-454, 2001.
31.
31. Schachinger V, Britten M, Zeiher A: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation101:1899-1906, 2000.
32.
32. Lefer D, Nakanishi K, Johnston W, et al: Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion of dogs. Circulation88:2337-2350, 1993.
33.
33. Jones S, Girod W, Palazzo A, et al: Myocardial ischemiareperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol276:H1567-H1573, 1999.
34.
34. Ozaki M, Kawashima S, Yamashita T, et al: Reduced hypoxic pulmonary vascular remodelling by nitric oxide from the endothelium. Hypertension37:322-327, 2001.
35.
35. Salerno L, Sorrenti V, Di Giacomo C, et al: Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Dis8:177-200, 2002.
36.
36. Rees D, Palmer R, Moncada S: Role of endothelium derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA86:3375-3378, 1989.
38. Mitaka C, Hirata Y, Yokoyama K, et al: A selective inhibitor for inducible nitric oxide synthase improves hypotension and lactic acidosis in canine endotoxic shock. Crit Care Med29:2156-2161, 2001.
39.
39. Feihl F, Waeber B, Liaudet L: Is nitric oxide overproduction the target of choice for the management of septic shock?Pharmacol Ther91:179-213, 2001.
40.
40. Samama C, Diaby M, Fellahi J, et al: Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology83:56-65, 1995.
41.
41. Behrendt D, Ganz P: Endothelial function: from vascular biology to clinical applications. Am J Cardiol90(suppl):40L-48L, 2002.
42.
42. Khan B, Harrison D, Olbrych M, et al: Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA93:9114-119, 1996.
43.
43. Lefer D, Jones S, Girod W, et al: Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol276:H1943-H1950, 1999.
44.
44. Gewaltig M, Kojda G: Vasoprotection by nitric oxide: Mechanisms and therapeutic potential. Cardiovasc Res55:250-260, 2002.
45.
45. Fukumura D, Gohongi T, Kadambi A, et al: Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA98:2604-2609, 2001.
46.
46. Guzik T, West N, Black E, et al: Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res86:E85-E90, 2000.
47.
47. Mugge A, Elwell J, Peterson T, et al: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxation in cholesterol-fed rabbits. Circ Res69:1293-1300, 1991.
48.
48. Sittipunt C, Steinberg K, Ruzinski J, et al: Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am J Resp Crit Care Med163:503-510, 2001.
49.
49. Gryglewski R, Palmer R, Moncada S: Superoxide anion is involved in the breakdown of endothelium derived relaxing factor. Nature320:454-456, 1986.
50.
50. Liu S, Beckman J, Ku D: Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasodilation. J Pharmacol Exp Ther268:1114-1121, 1994.
51.
51. Ludmer P, Selwyn A, Shook T, et al: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med315:1046-1051, 1986.
52.
52. Schachinger V, Britten M, Zeiher A: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation101: 1899-1906, 2000.
53.
53. Anderson T, Uehata A, Gerhard M, et al: Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol26:1235-1241, 1995.
54.
54. Heitzer T, Schlinzig T, Krohn K, et al: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation104:2673-2678, 2001.
55.
55. Treasure C, Klein J, Weintraub W, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med332:481-487, 1995.
56.
56. Tamai O, Matsuoka H, Itabe H, et al: Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation95:76-82, 1997.
57.
57. Laufs U.La Fata V.Plutzky J, et al: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation97:1129-1135, 1998.
58.
58. Kureishi Y, Luo Z, Shiojima I, et al: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med6:1004-1010, 2000.
59.
59. Napoli C, Ignarro L: Nitric oxide-releasing drugs. Annu Rev Pharmacol Toxicol43:97-123, 2003.
60.
60. Mancini G, Henry G, Macaya C, et al: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation94:258-265, 1996.
61.
61. Anderson T, Elstein E, Haber H, et al: Comparative study of ACE-inhibition, angiotensin-II antagonism, and calcium channel blockade on flow mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol35:60-66, 2000.
62.
62. Dhein S, Salameh A, Berkels R, et al: Dual mode of action of dihydropyridine calcium antagonists: A role for nitric oxide. Drugs58:397-404, 1999.
63.
63. Schwencke C, Yamamoto M, Okumura S, et al: Compartmentation of cyclic adenosine 3',5'-monophosphate signaling in caveolae. Mol Endocrinol13:1061-1070, 1999.
64.
64. Cotton J, Kearney M, Shah A: Nitric oxide and myocardial function in heart failure: Friend or foe?Heart88:564-566, 2002.
65.
65. Shah M, MacCarthy P: Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther86:49-86, 2000.
66.
66. Hare J, Givertz M, Creager M, et al: Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: Potentiation of beta-adrenergic inotropic responsiveness. Circulation97:161-166, 1998.
67.
67. Post H, Schulz R, Gres P, et al: No involvement of nitric oxide in the limitation of beta-adrenergic inotropic responsiveness during ischemia. Am J Physiol281:H2392-H2397, 2001.
68.
68. Barouch L, Harrison R, Skaf M, et al: Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature416:337-339, 2002.
69.
69. Krishnagopalan S, Kumar A, Parrillo J, et al: Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care8(5):376-388, 2002.
70.
70. Ahlner J, Andersson R, Torfgard K, et al: Organic nitrate esters. Clinical use and mechanisms of action. Pharmacol Rev4:351-423, 1991.
71.
71. Ignarro LJ: Nitric oxide as a unique signaling molecule in the vascular system: A historical review. J Physiol Pharmacol53:503-514, 2002.
72.
72. Munzel T, Sayegh H, Freeman B, et al: Evidence for enhanced vascular superoxide anion production in nitrate tolerance: A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest95:187-194, 1995.
73.
73. Skatchkov M, Larina L, Larin A, et al: Urinary nitrotyrosine content as a marker of peroxynitrite-induced tolerance to organic nitrates. J Cardiovasc Pharmacol Ther2:85-96, 1997.
74.
74. Molina C, Andresen J, Rapoport R, et al: Effect of in vivo nitroglycerin therapy on endothelium dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol10:371-378, 1987.
75.
75. Loscalzo J: Folate and nitrate-induced endothelial dysfunction. Circulation104:1086-1088, 2001.
76.
76. Kojda G, Stein D, Kottenberg E, et al: In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol25:763-773, 1995.
77.
77. Cooke J, Singer A, Tsao P. et al: Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest90:1168-1172, 1992.
78.
78. Laufs U, La Fata V, Plutzky J, et al: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation97:1129-1135, 1998.
79.
79. Wang S, Yan L, Wesley R, et al: Nitric oxide increases tumour necrosis factor production in differentiated U937 cells by decreasing cyclic AMP. J Biol Chem272:5959-5965, 1997.
80.
80. Weinberger B, Fakhrzadeh L, Heck D, et al: Inhaled nitric oxide primes lung macrophages to produce reactive oxygen and nitrogen intermediates. Am J Respir Crit Care Med158:931-938, 1998.
81.
81. Kinsella J, Parker T, Galan H. et al: Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res41:457-463, 1997.
82.
82. Gries A, Herr A, Motsch J, et al: Randomized, placebocontrolled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers. Thromb Haemost83:309-315, 2000.
83.
83. Rossaint R, Falke K, Lopez F, et al: Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med328:399-405, 1993.
84.
84. Barbera J, Roger N, Roca J, et al: Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet347:436-440, 1996.
85.
85. Busch T, Deja M, Boemke W: Endothelin-1 plasma levels influence efficacy of inhaled nitric oxide in experimental acute lung injury. Am J Resp Crit Care Med165:A783-A783, 2002 (abstr).
86.
86. Dellinger R, Zimmerman J, Taylor R, et al: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med26:15-23, 1998.
87.
87. Michael J, Barton R.Saffle J, et al: Inhaled nitric oxide versus conventional therapy: Effect on oxygenation in ARDS. Am J Resp Crit Care Med157:1372-1380, 1998.
88.
88. Meade M, Herridge M: An evidence based approach to acute respiratory distress syndrome. Respir Care46:1368-1376, 2001.
90. Snow D, Gray S, Ghosh S, et al: Inhaled nitric oxide in patients with normal and increased pulmonary vascular resistance after cardiac surgery. Br J Anaesth72:185-189, 1994.
91.
91. Schulze-Neick I, Bultmann M, Werner H, et al: Right ventricular function in patients treated with inhaled nitric oxide after cardiac surgery for congenital heart disease. Am J Cardiol80:360-363, 1997.
93. Kaye M: The Registry of the International Society for Heart and Lung Transplantation: Tenth official report-1993. J Heart Lung Transplant12:541-548, 1993.
94.
94. Semigran M, Cockrill B, Kacmarek R, et al: Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol24:982-988, 1994.
95.
95. Loh E, Stamler J, Hare J, et al: Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation90:2780-2785, 1994.
96.
96. Ichinose F, Adrie C, Hurford W, et al: Selective pulmonary vasodilation induced by aerosolized Zaprinest. Anesthesiology88:410-416, 1998.
97.
97. Michelakis E, Tymchak W, Lien D, et al: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation105:2398-2403, 2002.
98.
98. Lowson S: Inhaled alternatives to nitric oxide. Anesthesiology96:1504-1513, 2002.
99.
99. Vane J, Botting R: Pharmacodynamic profile of prostacyclin. Am J Cardiol75:3A-1OA, 1995.
100.
100. Kawakami M, Ishibashi S, Ogawa H, et al: Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular endothelial cells. Biochem Biophys Res Commun141:482-485, 1986.
101.
101. Gryglewski R, Bunting S, Moncada S: Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins12:685-713, 1976.
102.
102. Moncada S, Gryglewski R, Bunting S: A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins12:715-737, 1976.
103.
103. Walmrath D, Schneider T, Pilch J, et al: Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet342:961-962, 1993.
104.
104. Zwissler B, Kemming G, Habler O, et al: Inhaled prostacyclin versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Resp Crit Care Med154:1671-1677, 1996.
105.
105. Van Heerden P, Barden A, Michalopoulos N, et al: Dose response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest117:819-827, 2000.
106.
106. Haraldsson A, Kieler-Jensen N, Ricksten S: Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery or heart transplantation: A pharmacodynamic study. J Cardiothorac Vasc Anesth10:864-868, 1996.
107.
107. Schroeder R, Wood G, Plotkin, JS, et al: Intraoperative use of inhaled PGI2 for acute pulmonary hypertension and right ventricular failure. Anesth Analg91:291-295, 2000.
108.
108. Della Rocca G, Coccia C, et al: Inhaled aerosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation. Transplant Proc33:1634-1636, 2001.
109.
109. Lowson S, Doctor A, Walsh B, et al: Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med30:2762-2764, 2002.
110.
110. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis45(3):213-224, 2002.
111.
111. Olschewski H, Simonneau G, Sitbon O, et al: Inhaled iloprost in severe pulmonary hypertension. N Engl J Med347:322-329, 2002.
112.
112. Galie N, Humbert M, Vachiery J, et al: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension. A randomized doubleblind placebo-controlled trial. J Am Coll Cardiol39:1496-1502, 2002.
113.
113. Langleben D, Christman B, Barst R, et al: Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patient with primary pulmonary hypertension. Am Heart J143:E4-E4, 2002.
114.
114. Channick R, Simonneau G.Sitbon O, et al: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study. Lancet358:1119-1123, 2001.
115.
115. Rubin L, Badesch D, Barst R, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med346:896-903, 2002.
116.
116. Barst R, Rich S, Widlitz A, et al: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest121:1860-1868, 2002.
